Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50,580,036
-
Total 13F shares
-
7,587,249
-
Share change
-
+259,060
-
Total reported value
-
$59,160,000
-
Price per share
-
$7.81
-
Number of holders
-
17
-
Value change
-
+$2,023,036
-
Number of buys
-
7
-
Number of sells
-
3
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q1 2017
As of 31 Mar 2017,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,587,249 shares.
The largest 10 holders included
Novo A/S, SV Health Investors, LLC, RA CAPITAL MANAGEMENT, LLC, INTERWEST VENTURE MANAGEMENT CO, INTERNATIONAL BIOTECHNOLOGY TRUST PLC, Vivo Capital, LLC, VHCP Management II, LLC, VANGUARD GROUP INC, EVENTIDE ASSET MANAGEMENT, LLC, and BOOTHBAY FUND MANAGEMENT, LLC.
This page lists
17
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.